3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
4
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Polycystic Ovary Syndrome
2
Infertility
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Leiomyoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal
1
Breast Neoplasm Female
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Anovulation
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced HR+/HER2- Breast Cancer
1
Interventions
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sutures
1
Sunitinib
1
Specimen Handling
1
Radionuclide Imaging
1
Paclitaxel
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Nuclear Medicine Department, Hospital
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Letrozole
×
30 days
×
Clear all
No trials found.